Single B cell technology has emerged as a powerful method for discovering and developing antibodies, particularly in the context of cancers like bladder cancer. This approach allows researchers to isolate and analyze individual B cells that produce specific antibodies against tumor-associated antigens. At Alfa Cytology, we have an advanced Beacon single B-cell antibody development platform, which saves you at least 2 months of antibody development cycle.
Alfa Cytology possesses the expertise and resources to deliver a robust workflow for single B-cell antibody development, ensuring precise isolation, characterization, and optimization of high-affinity antibodies for diverse applications.
Animal Immunization
5-7 weeks
PBMC Isolation
1 week
Beacon® Single-Cell Sorting
1 day
Single B Cell Sequencing
1 week
Recombinant Antibody Expression
1-2 weeks
Case Study of TAA-specific Antibody Screening
Alfa Cytology has extensive experience in TAA-specific antibody screening, demonstrated through successful case studies that showcase our ability to identify and validate high-affinity antibodies targeting tumor-associated antigens.
Key Advantages
Faster Processing
High Specificity
High Throughput
Improved Affinity
Single B cell technology represents a cutting-edge approach to antibody discovery in bladder cancer, offering the potential for more effective and targeted therapies. With our extensive expertise and integrated services, we are your trusted partner in accelerating bladder cancer research and driving breakthroughs in diagnostics and therapeutics. Please contact us for more information.
